New research reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Findings released in a major medical journal points out that while overweight individuals frequently drop a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"People buying such medications should be aware of the risk of fast weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight within about a year and a half.
Analyzing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, compared the effects of these new drugs with other pills.
Scientists note that people who shed pounds through dieting generally have a slower creep back—approximately 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Doctors suggest the way of the jabs accounts for the amplified weight return.
These medications imitate a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its own natural hormone, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
The NHS advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, given the significant potential of relapse, the therapy should be considered life-long.
This opinion is supported by drug manufacturers, who note that the results "emphasize the persistent nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Testimonies
Users who have stopped the medication report a powerful resurgence of hunger.
"It felt as if a switch that goes on and you become extremely hungry," said a patient.
The struggle is compounded if patients have not established lasting dietary or behavioural modifications during therapy.
Widespread Interest
Figures show that millions of people in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is higher among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and long-term success relies on combined lifestyle support.
